Engagement with mobile chat-based intervention associated with higher abstinence rates at three and six months
FRIDAY, July 5, 2024 (HealthDay News) — Higher levels of engagement with a chat-based smoking cessation intervention are associated with greater biochemically validated tobacco abstinence at three and six months, according to a study published online June 26 in JAMA Network Open.
Yajie Li, from the School of Nursing at the University of Hong Kong, and colleagues conducted a secondary analysis of a cluster randomized clinical trial involving 624 cigarette smokers receiving chat-based smoking cessation support via mobile instant messaging for three months.
The researchers identified four distinct engagement trajectories: a low engagement group (71.6 percent), in which participants maintained very low engagement throughout; rapid-declining group (13.8 percent), in which participants began with moderate engagement and rapidly decreased to a low level; gradual-declining group (9.3 percent), in which participants had high initial engagement that gradually decreased to a moderate level; and high engagement group (5.3 percent), in which participants maintained high engagement throughout. The six-month validated abstinence rates were significantly higher in the rapid-declining group (adjusted relative risk [aRR], 3.30), gradual-declining group (aRR, 5.17), and high engagement group (aRR, 4.98) compared with the low engagement group. For three-month validated abstinence, the corresponding aRRs were 4.03, 5.25, and 9.23.
“Improving engagement with digital interventions may increase intervention benefits,” the authors write.
Financial Incentives Boost Tobacco Abstinence in Underserved Adults
Problematic Media Use Tied to Sleep Disturbances in Children Diagnosed With Enuresis
Postdischarge Text Messages Boost Pursuit of Public Benefits Assistance
Smartphone Apps May Boost Smoking Cessation
Most Specialty Oral Anticancer Meds for Blood Cancers Are Initially Rejected by Insurers
Drug Interactions Reducing Contraceptive Effectiveness Common in Epilepsy
1 in 3 With Lupus Take Supplements, Medications With Potential for Interactions
Holding DMARDs at Time of COVID-19 Vaccine Not Warranted in Those With Inflammatory Arthritis